MBLUKP · Clinical consequences of mannose binding lectin dysfunction.
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2005-01-01 → 2005-12-31
- EU contribution
- €40,000
- Participants
- 1
- Scheme
- ERG
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - MBLUKP (Clinical consequences of mannose binding lectin dysfunction)
Mannose-binding lectin (MBL) is an important component of the innate immune system which is present at birth. MBL acts to protect us from bacteria and viruses, particularly at times when other forms of protection are limited. These times are, at birth, in the first few years of life and when something goes wrong with our immune systems such as during chemotherapy for cancer, HIV infection and diseases such as cystic fibrosis. About a third of humans have low levels of this protein. Such individuals may be liable to get infections. In this study, we looked at the role of MBL in neonates born prematurely. The project was based in Poland and the UK and examined 166 premature neonates (99 Polish and 67 British) to assess the relationship. MBL level, function and genotype were examined and related to neonatal susceptibility to infection. Our initial results indicate that in very premature babies, MBL deficiency is a risk factor for infection. Furthermore all babies in the first few days of life have low MBL levels and this may explain why so many infections occur in the first week of life in premature babies. MBL replacement therapy will be available in the next few years. This group of patients may benefit from such therapy.
Data: CORDIS, © European Union
Project objective
Infection remains an important cause of morbidity and mortality in neonates. We have established that MBL defects can influnce the rate of infection in this patient population. Therefore if we understood more about importance and mechanisms of this MBL dys function we could potentially modify our approach to managing neonatal infection. This project is a logical extension of work performed while I was a Marie Curie Individual Reseach Fellow. The basis of this project stems from recent work which shows that c omplement activating capacity of MBL is related to levels of MASP-2, an MBL associated serine protease. The proposed study will explore the relationship between MASP-2 activity and susceptibility to infection. This work will be complemented by genetic stud ies relating MASP-2 genotype and MASP-2 levels. The results of this project will directly inform on the role of MBL- MASP in neonatal susceptibility to infection. In addition it will allow me to reintegrate back to Poland and facilitate two way scientific interactions between Poland and the UK.
Original text from CORDIS.
Participants
- POLISH MOTHERS MEMORIAL HOSPITAL- RESEARCH INSTITUTE · LODZCoordinatorCity levelPoland
Links
Data: CORDIS, © European Union